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Received March 3, 2014; accepted May 21, 2014AbstractWe report a case of complete atrioventricular block (CAVB) with ventricular asystole and recurrent AVBs due to all-trans retinoic acid
(ATRA). A 57-year-old man with acute promyelocytic leukemia was undergoing induction therapy with ATRA and developed episodic seizures
with altered consciousness on the 14th day and then CAVB followed by cardiac arrest on the 15th day. Although he initially recovered after
resuscitation, he suffered from recurrent CAVB, which persisted for 3 days despite immediate ATRA discontinuation. He then received ATRA
retreatment with reduction of dosage, but a high-degree AVB recurred on the 5th day. After discontinuation of ATRA therapy, the patient
recovered 3 days later without any cardiovascular event during follow-up. The serial electrocardiogram changes suggested an infra-Hisian block
with possible ATRA dose-response relationship. To our knowledge, this is the first established case of ATRA-induced CAVB in the literature. We
suggest clinical alertness for this life-threatening complication.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Acute promyelocytic leukemia (APL) comprises 10e15%
of acute myelocytic leukemia and is characterized by marked
proliferation of leukemic promyelocytes in the bone marrow,
life-threatening coagulopathy, and a specific reciprocal trans-
location of t(15;17). APL used to be a highly lethal subtype of
acute leukemia, with up to a 47% early hemorrhagic death rate
before or during induction chemotherapy and a 2-year survival
of 30e50%.1 However, the advent of all-trans retinoic acid
(ATRA) in the 1980s revolutionized the therapy of APL,Conflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assleading to dramatic decreases in early hemorrhagic death, to
5e10%, and overall survival, to 85e90%.2
Herein, we report a case of APL developing a very rare but
life-threatening CAVB during ATRA therapy. The causal role
of ATRA was established by rechallenge, and the serial elec-
trocardiogram (EKG) changes suggested a possible dose-
response relationship.2. Case report
A 57-year-old man with type II diabetes mellitus was
admitted due to fever and leukopenia. The blood routine
revealed leukopenia (1.6  109/L), anemia (10 g/dL), and
thrombocytopenia (24  109/L) with immature white cells.
The bone marrow study suspected APL, but septicemia due to
Acinetobacter baumannii had to be treated during the initial
course with intravenous ciprofloxacin that was later changed
to cefepime due to persistent fever.ociation. All rights reserved.
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translocation of APL [46, XY, t(15;22;17)(q24;q13;q21)],
ATRA (45 mg/m2/d) was given orally. The patient experienced
an ATRA-related mild headache and bone pain, but mucositis
became aggravated later and the dosage was reduced to 75%
from the 5th day of therapy. Molecular study reported a long-
type PML/RARa fusion mRNA 2 weeks later.
On the 13th day of ATRA therapy, an episode of transient
aphasia and general paresis occurred, but urgent computed
tomography of the brain showed negative results. On the
following day, the patient then developed episodic generalized
convulsions with delirium. Laboratory surveys revealed no
significant abnormalities. Valproic acid was given under sus-
picion of myoclonic seizure to relieve the symptoms.
On the 15th day of ATRA therapy, the patient experienced
another episode of fluctuating consciousness disturbance in the
morning. Bedside EKG monitoring showed a first-degree AVB
with a regular heartbeat of 94 beats/min (Fig. 1A), and later,
the EKG showed CAVB with ventricular escape (Fig. 1B). In
the afternoon, a complete loss of consciousness suddenly
occurred after yawning. The patient was found unresponsive
and without spontaneous breathing or heartbeat. A shot of
epinephrine was given immediately followed by cardiopul-
monary resuscitation. The ventricular rate resumed after
treatment, but severe bradycardia recurred due to CAVB
2 hours later, necessitating a second resuscitation.
We stopped the ATRA therapy and administered temporary
cardiac pacing for the patient; an echocardiogram did not
demonstrate any structural defect of the heart, but varying
degrees of heart blocks persisted for 3 days (Fig. 2AeC)Fig. 1. Serial electrocardiogram changes before and after the life-threatening compl
AVB (P-R interval ¼ 360 ms); (B) 2 hours before cardiac arrest: complete AVB wbefore conversion to sinus rhythm on the 20th day. Due to
suspicion of ATRA as the inciting agent, we reduced its dose
during retreatment and placed the patient under close EKG
telemetric monitoring. However, on the 5th day of treatment,
high-degree AVB with 2:1 AV conduction (Fig. 2D) recurred
without significant clinical symptoms. The drug was dis-
continued immediately, and the AVB disappeared gradually
over 3 days without further recurrence. Throughout the epi-
sodes, there was no evidence of retinoic acid syndrome (RAS),
such as the characteristic features of fever, respiratory distress,
pulmonary infiltration, pleural or pericardial effusion, or
weight gain, nor did the patient receive any arrhythmogenic or
node-blocking medication.
3. Discussion
The retinoid acids are derived from vitamin A, and bind to
the nuclear retinoic acid receptors (RARs). The RARs then
undergo heterodimerization and bind to DNA to facilitate gene
transcription and control post-transcriptional expression. The
t(15;17) translocation of APL fuses the PML (promyelocytic
leukemia) gene to the gene RARa, and the resultant fusion
gene PML-RARa produces the PML/RARa oncoprotein,
which forms homodimer and competitively blocks granulo-
cytic differentiation.2 The pharmacological dose of ATRA
leads to dissociation of the nuclear corepressor, which pre-
sumably facilitates APL maturation.3
ATRA has been a relatively safe drug, with few serious
adverse effects as compared to conventional chemotherapy.
The more common side effects, including headache, dryete atrioventricular block (AVB): (A) 7 hours before cardiac arrest: first-degree
ith ventricular escape (15th day of all-trans retinoic acid).
Fig. 2. Delayed recovery of heart blocks with recurrence after rechallenge: (A) 38 hours after resuscitation: second-degree atrioventricular block (AVB; Mobitz
type I); (B) 63 hours after resuscitation: complete AVB with pacing-dependence and intermittent ventricular asystole; (C) 91 hours after resuscitation: first-degree
AVB; and (D) recurrence of high-degree AVB on Day 5 of all-trans retinoic acid rechallenge.
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usually mild. RAS is a special side effect of ATRA, and
occurs in 15% of APL patients during the 2nd day to the 3rd
week of ATRA therapy, with a mortality rate of 2%. The
proposed mechanisms of RAS include release of vasoactive
cytokines from cytoplasmic granules, expression of surface
adhesion molecules, and chemotaxis of differentiating
myeloid cells. Prompt administration of high-dose dexa-
methasone at the first signs of unexplained dyspnea, weight
gain, fever, and pulmonary infiltrate is critical for an optimal
outcome.4
ATRA-related arrhythmias are rarely reported in the liter-
ature. A case of Wenckebach phenomenon was reported with
RAS-related pericardial effusion on the 9th day of ATRA
therapy but recovered after steroid treatment.5 Recurrent sinus
bradycardias due to ATRA during APL treatment was reported
in a 3-year-old boy.6 Sinus node dysfunction withasymptomatic junctional bradycardia was also reported in a
28-year-old woman after sepsis and RAS related to ATRA and
anthracycline-based chemotherapy.7
There was only one previous case report of suspected
ATRA-related CAVB, which was reported in the Japanese
literature.8 The CAVB presented as an unexplained sudden
AdamseStokes syncope on the 25th day of induction therapy
after enocitabine, mitoxantrone, and ATRA therapy. The cause
of CAVB was uncertain, hence ATRA was given for 4 more
days before discontinuation; the arrhythmia persisted for
15 days before recovery.8
The mechanism underlying ATRA-related heart blocks is
unknown. A previous study of an ischemiaereperfusion model
in rats reported that a perfusion of ATRA (15e20 mM) could
significantly reduce the incidence and severity of ventricular
arrhythmias. The authors speculated that inhibition of auto-
maticity/excitability may result from effects of ATRA on
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responsive to stimuli.9 In our case, the first attack of CAVB
occurred on the 15th day of ATRA therapy and then persisted
for 3 days. Under low-dose rechallenge, the second attack was
milder and shorter, occurred as asymptomatic high-grade AVB
on the 5th day, and persisted for 3 days. The onset and severity
of the heart blocks in our case may suggest a possible rela-
tionship between the drug level and the AV blocks. According
to the devastating clinical course and wide QRS complex of
the escape rhythm, the level of conduction block may have
been due to an infra-Hisian block. Considering the very rare
occurrence and the dosage-temporal pattern with ATRA usage
in this case, we suspect that idiosyncratic myocardial sensi-
tivity or heterogeneity in drug metabolism may have played a
part in its pathogenesis.
A recent population-based survey in the USA revealed a
much higher early death rate, of 17.3%, than those reported in
modern trials, due to therapy delays during diagnostic
workups. Since current guidelines advocate regarding suspi-
cion of APL as a medical emergency necessitating prompt
commencement of ATRA therapy prior to genetic confirma-
tion, awareness of this life-threatening complication is
important for clinicians.10
In this case report, we have established the causal rela-
tionship of ATRA and CAVB by rechallenge. Although the
pathophysiology was obscured, the serial EKG changes of this
case suggest a possible doseeresponse effect. Further explo-
ration into the myocardial electrophysiology of ATRA is
necessary to disclose the underlying mechanisms and the
drug's potential role in the management of cardiac arrhythmia.References
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